Overview Financials News + Filings IR Vault Key Docs Charts Transactions Holdings Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Asset disposition Quarterly results Appointed director CC transcript
|
BRISTOL MYERS SQUIBB CO (BMY)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/05/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of MyoKardia, Inc. Buyout |
10/05/2020 |
GN
| MYOKARDIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MYOK and Encourages Investors to Contact the Firm |
06/08/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT |
06/03/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT |
05/28/2020 |
GN
| WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer |
05/27/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT |
05/15/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT |
04/21/2020 |
GN
| WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer |
03/25/2019 |
GN
| Report: Developing Opportunities within Bristol-Myers Squibb, AutoNation, FirstEnergy, Charles River Laboratories International, Yum! Brands, and AGNC Investment — Future Expectations, Projections Moving into 2019 |
03/06/2019 |
GN
| Analysis: Positioning to Benefit within Bristol-Myers Squibb, AAR, Central Garden & Pet, Alexion Pharmaceuticals, Tribune Media, and Civitas Solutions — Research Highlights Growth, Revenue, and Consolidated Results |
01/04/2019 |
GN
| Candel Therapeutics Completes $28.7 Million Series B Financing |
01/04/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Celgene Corporation to Bristol-Myers Squibb Company is Fair to Shareholders |
12/31/2018 |
GN
| Report: Exploring Fundamental Drivers Behind Bristol-Myers Squibb, Ascena Retail Group, OrthoPediatrics, Star Bulk Carriers, Leidos, and ADOMANI — New Horizons, Emerging Trends, and Upcoming Developments |
08/08/2018 |
GN
| Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers Squibb, and Equity Lifestyle Properties — Future Expectations, Projections Moving into 2018 |
03/28/2018 |
GN
| The Klein Law Firm Reminds Investors of a Class Action on Behalf of Bristol-Myers Squibb Company Shareholders and a Lead Plaintiff Deadline of April 10, 2018 (BMY) |
03/23/2018 |
GN
| BMY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Bristol-Myers Squibb Company and a Lead Plaintiff Deadline of April 10, 2018 |
03/22/2018 |
GN
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Bristol-Myers Squibb Company of a Class Action and a Lead Plaintiff Deadline of April 10, 2018 – BMY |
03/09/2018 |
GN
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018 |
03/05/2018 |
GN
| The Klein Law Firm Announces a Class Action Filed on Behalf of Bristol-Myers Squibb Company Shareholders and a Lead Plaintiff Deadline of April 10, 2018 (BMY) |
02/28/2018 |
GN
| BMY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Bristol-Myers Squibb Company and a Lead Plaintiff Deadline of April 10, 2018 |
02/22/2018 |
GN
| Pomerantz Law Firm Announces the Filing of a Class Action against Bristol-Myers Squibb Company and Certain Officers – BMY |
02/21/2018 |
GN
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018 |
02/12/2018 |
GN
| SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company (NYSE: BMY) To Contact Brower Piven Before The Lead Plaintiff Deadline |
01/25/2018 |
GN
| Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone |
01/08/2018 |
GN
| Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time |
12/05/2017 |
GN
| Consolidated Research: 2018 Summary Expectations for Skechers U.S.A., Bristol-Myers Squibb, Mastercard, Container Store, Signature Bank, and Bridgepoint Education — Fundamental Analysis, Key Performance Indications |
11/07/2017 |
GN
| New Research: Key Drivers of Growth for Coty, Bristol-Myers Squibb, Carnival, Agenus, Steel Dynamics, and Impax Labs - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production |
11/06/2017 |
GN
| BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™ |
10/30/2017 |
GN
| FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax™ in Patients with Advanced Breast Cancer |
|
|